Trial · NCT03617289
Efficacy of Magnesium Sulfate on Reducing Renal Colic in the Emergency Department
NCT03617289, Not applicable, Completed, Henry Ford Health System; results first posted 2023-03-24
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy of Magnesium Sulfate on Reducing Renal Colic in the Emergency Department. Trials, record NCT03617289. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03617289
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy of Magnesium Sulfate on Reducing Renal Colic in the Emergency Department
- NCT number
- NCT03617289
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 37 participants, actual
- Lead sponsor
- Henry Ford Health System
- Conditions
- Renal Colic
- Interventions
- Magnesium Sulfate, D5W
- First posted
- 2018-08-06
- Last updated
- 2023-03-24
- Results first posted
- 2023-03-24
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pain Score Change | 1 hour after the completion of treatment medication (Placebo or Study Drug) | We asked the patient's pain score on a scale of 0-10 with 10 being the highest amount of pain and 0 no pain, before and after treatment (approximately 1 hour). Primary Outcome was the change in score before and after treatment. |
| Secondary | Percentage of Participants Requiring Opiates for Additional Pain Control | Any opiate administration required after re-evaluation of pain score after initial treatment with either placebo or study drug | We analyzed how many patients required additional pain control with opiates between the two treatment groups. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Pain Score Change | 1 hour after the completion of treatment medication (Placebo or Study Drug) | Units on a Scale | MEAN | |
| SECONDARY | Percentage of Participants Requiring Opiates for Additional Pain Control | Any opiate administration required after re-evaluation of pain score after initial treatment with either placebo or study drug | percentage of participants | NUMBER |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Pain Score Change | Treatment | -3.4 | Standard Deviation 2.7 | Units on a Scale | |
| Pain Score Change | Placebo | -3.6 | Standard Deviation 3.9 | Units on a Scale | |
| Percentage of Participants Requiring Opiates for Additional Pain Control | Treatment | 16.7 | percentage of participants | ||
| Percentage of Participants Requiring Opiates for Additional Pain Control | Placebo | 47.4 | percentage of participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Treatment | 18 | |
| Overall Study | STARTED | Placebo | 19 | |
| Overall Study | COMPLETED | Treatment | 18 | |
| Overall Study | COMPLETED | Placebo | 19 | |
| Overall Study | NOT COMPLETED | Treatment | 0 | |
| Overall Study | NOT COMPLETED | Placebo | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Treatment | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | Treatment | 0 | 18 |
| Total, other adverse events | Placebo | 0 | 19 |
| Total, serious adverse events | Treatment | 0 | 18 |
| Total, serious adverse events | Placebo | 0 | 19 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Treatment vs Placebo: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03617289
GET https://conductscience.org/api/trials/v1/NCT03617289/registered